Vanessa Research shares their organizational growth and strategic objectives with
BUDAPEST, January 16, 2020 — Vanessa Research, (VR) — a biomedical company transforming the healthcare landscape by developing and commercializing innovative products in areas of unmet medical needs— participated in an interview with Pharma Boardroom, the premier website for C-Level executives, consultants, regulators and vendors working in Healthcare & the Life Sciences globally. László Dinca, Managing Director of Vanessa Research Hungary, joined Pharma Boardroom to share his insights on the company’s rare disease portfolio and their entrance into the pharmaceutical contract manufacturing landscape. The interview is available at pharmaboardroom.com/interviews/laszlo-dinca-managing-director-vanessa-research-hungary/.
During the interview, Dinca addressed the strategic intentions behind the recent acquisition of HG Biotech (f/k/a/ Hungaro-Gal Pharmaceutical Manufacturing), the significance of Hungary for VR, and the future direction of the company. He highlighted how the acquisition of HG Biotech gave VR manufacturing capabilities that allows them to control and ensure the supply and the quality of their medicine as well as facilitate VR’s access to the European market once Shylicine™, a cocktail drug candidate for treating Microvillus Inclusion Disease (MVID), is authorized.
Pharma Boardroom interviews with top pharma companies worldwide and releases a global Health & Life Sciences Review annually, an opportunity to showcase the significant advancement of health and wellness underway throughout the nation. The 2020 edition of the Hungary Healthcare & Life Sciences Review will include VR as a key player in the Hungarian pharmaceutical landscape.
In response to a question regarding the company’s five-year agenda, Dinca stated: “The main mission is to produce drugs for MVID and cholera. Furthermore, we aim to solidify the strong foundations of the contract manufacturing operations at HG Biotech, and to build upon them. The idea is to bring these drugs to patients as quickly as possible and we believe that in-house manufacturing is the best way forward for us. …VR aims to retain and strengthen relationships with HG Biotech’s current clients while simultaneously working to build new partnerships.”
With their newly formed division: pharmaceutical manufacturing, VR is one step closer to achieving their long-term vision of bringing medicines to patients around the world, and serving overlooked healthcare markets. VR plans to continue creating an added value for their patients, the healthcare industry, and the Hungarian business ecosystem, fulfilling the company’s mission to “give hope where none existed.’’
About Vanessa Research
Vanessa Research (VR) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets that are often overlooked. VR’s continually-expanding pipeline of innovative pharmaceuticals, medical devices, and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare, lethal microvillus inclusion disease.
VR is based in Hamden, Connecticut, with offices in Budapest, Hungary; Munich, Germany; and Navarre, Spain.
Director of Marketing and Communications
925 Sherman Avenue,
Hamden, CT, 06514 USA